Insulet Corporation (NASDAQ:PODD) Shares Bought by IFM Investors Pty Ltd

IFM Investors Pty Ltd boosted its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 8.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,180 shares of the medical instruments supplier's stock after acquiring an additional 1,098 shares during the quarter. IFM Investors Pty Ltd's holdings in Insulet were worth $3,724,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in PODD. SBI Securities Co. Ltd. bought a new position in Insulet in the fourth quarter valued at approximately $36,000. Itau Unibanco Holding S.A. bought a new position in shares of Insulet in the fourth quarter valued at about $42,000. Golden State Wealth Management LLC lifted its stake in shares of Insulet by 553.1% during the 1st quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier's stock worth $55,000 after buying an additional 177 shares during the last quarter. Assetmark Inc. boosted its holdings in shares of Insulet by 1,447.1% during the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after buying an additional 246 shares during the period. Finally, Coppell Advisory Solutions LLC raised its holdings in Insulet by 135.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock valued at $74,000 after acquiring an additional 162 shares during the period.

Insider Activity at Insulet

In other news, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the transaction, the senior vice president directly owned 23,180 shares in the company, valued at approximately $7,382,134.60. This trade represents a 18.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.39% of the company's stock.

Insulet Stock Performance

Shares of PODD traded down $4.19 on Tuesday, reaching $296.51. The company's stock had a trading volume of 714,481 shares, compared to its average volume of 720,222. The stock's 50 day simple moving average is $303.89 and its two-hundred day simple moving average is $279.37. The stock has a market capitalization of $20.87 billion, a P/E ratio of 53.33, a PEG ratio of 2.69 and a beta of 1.35. The company has a debt-to-equity ratio of 1.21, a current ratio of 4.47 and a quick ratio of 3.63. Insulet Corporation has a 12-month low of $173.00 and a 12-month high of $329.33.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping the consensus estimate of $0.81 by $0.21. The business had revenue of $569.00 million for the quarter, compared to analysts' expectations of $543.20 million. Insulet had a net margin of 18.29% and a return on equity of 22.25%. The business's quarterly revenue was up 28.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.73 EPS. Research analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on PODD shares. Citigroup reaffirmed a "buy" rating on shares of Insulet in a research report on Tuesday. The Goldman Sachs Group assumed coverage on shares of Insulet in a research report on Friday, May 30th. They set a "buy" rating and a $380.00 price target on the stock. Barclays boosted their target price on Insulet from $234.00 to $266.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 30th. Wolfe Research raised shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target on the stock in a report on Tuesday, May 13th. Finally, Truist Financial began coverage on Insulet in a report on Monday, June 16th. They issued a "buy" rating and a $365.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, Insulet has a consensus rating of "Moderate Buy" and an average price target of $321.00.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.